Kezar Life Sciences, Inc. (NASDAQ:KZR) Receives $6.00 Average Target Price from Analysts

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR) have received an average recommendation of “Reduce” from the six brokerages that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $6.00.

A number of analysts recently weighed in on KZR shares. William Blair restated a “market perform” rating on shares of Kezar Life Sciences in a report on Friday, October 17th. Wall Street Zen raised Kezar Life Sciences to a “sell” rating in a research note on Saturday, September 13th. TD Cowen cut Kezar Life Sciences from a “strong-buy” rating to a “strong sell” rating in a report on Friday, October 17th. Wells Fargo & Company set a $5.00 target price on Kezar Life Sciences and gave the stock an “equal weight” rating in a research report on Friday, October 17th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kezar Life Sciences in a research report on Wednesday, October 8th.

Institutional Trading of Kezar Life Sciences

Institutional investors have recently made changes to their positions in the stock. BML Capital Management LLC grew its stake in shares of Kezar Life Sciences by 738.6% in the first quarter. BML Capital Management LLC now owns 408,138 shares of the company’s stock worth $1,992,000 after acquiring an additional 359,470 shares during the last quarter. Woodline Partners LP acquired a new position in Kezar Life Sciences during the 1st quarter valued at $125,000. Stonepine Capital Management LLC boosted its holdings in Kezar Life Sciences by 69.9% in the 2nd quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock valued at $778,000 after purchasing an additional 69,859 shares during the period. Peapod Lane Capital LLC grew its position in Kezar Life Sciences by 9.3% in the 3rd quarter. Peapod Lane Capital LLC now owns 125,773 shares of the company’s stock worth $491,000 after purchasing an additional 10,650 shares during the last quarter. Finally, Landscape Capital Management L.L.C. acquired a new stake in Kezar Life Sciences in the 3rd quarter worth $51,000. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Price Performance

KZR stock opened at $6.18 on Tuesday. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.65. The stock’s fifty day simple moving average is $4.89 and its 200-day simple moving average is $4.46. The stock has a market capitalization of $45.24 million, a price-to-earnings ratio of -0.73 and a beta of 0.70. The company has a quick ratio of 7.29, a current ratio of 7.07 and a debt-to-equity ratio of 0.02.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Wednesday, November 12th. The company reported ($1.53) earnings per share for the quarter, beating the consensus estimate of ($1.81) by $0.28. Equities research analysts expect that Kezar Life Sciences will post -4.39 EPS for the current year.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.